News Nestle bids to take control of Seres’ C diff drug Vowst Swiss food giant Nestlé has said it wants to take full ownership of Seres Therapeutics’ Vowst microbiome therapy for Clostridiodes difficile infections (CDI), upg
R&D Why gut bacteria is the next frontier in medicine Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.
News Vedanta scores $106.5m to take microbiome drug into ph3 In the face of a challenging biotech financing environment, Vedanta Bio has ra
News FDA accepts review of SeresTx BLA for oral microbiome therap... The FDA has accepted for review Seres Therapeutics’ Biologics License Application (BLA) for SER-109, an investigational oral
News Digital support reduces GLP-1 dose needed for weight loss Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.